Lanman Appointed to Biolase Board

Dental laser developer Biolase Inc. has appointed biotechnology entrepreneur Richard Lanman to its board of directors.

Lanman is a board-certified neurologist and physiatrist currently serving as the chief medical officer at Guardant Health Inc. During his career, he has also served on a number of boards and authored 45 articles that have been published in peer-reviewed scientific journals.

Lanman replaces outgoing director Fredrick Moll who is resigning from the board due to his commitments associated with his role as CEO of Auris Surgical Robotics Inc.

“His extensive board and executive management experience and his focus on developing and commercializing disruptive medical technologies and procedures make Dr. Lanman a terrific addition to our board,” said Johnathan Lord, chairman of the board. “We look forward to his advice and counsel as our board, together with President and CEO Harold Flynn and his executive management team, continue to concentrate on establishing Biolase and its innovative dental laser systems as the standard of care in dentistry. I would also like to thank Dr. Moll for his many years of valuable service to Biolase and wish him the very best.”

Lanman joined Guardant Health Inc. in September 2014. He has planned and executed clinical and analytical validity, along with clinical utility studies, to bring novel cell-free DNA next generation sequencing technology to widespread adoption. Lanman’s previous posts include positions at Veracyte Inc., chief medical officer at diaXeus and Etherotech, medical director and senior vice president of San Jose Medical Group and chief of quality at Kaiser Permanente.

Biolase develops, manufactures, markets and sells laser systems in dentistry and medicine.